BLTE Earnings Date: Nov 9, 2026 (Estimated) — Belite Bio, Inc
NASDAQ · Healthcare · Biotechnology
Updated
When is BLTE's next earnings date?
Belite Bio, Inc (BLTE) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.79.
How did BLTE do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Belite Bio, Inc posted EPS of -$0.54 versus the -$0.73 estimate, a beat of 29.9%. Revenue was $0. The stock's 1-day post-earnings move was -7.1%.
How much does BLTE stock move after earnings?
BLTE beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.2% (up or down) in the day after earnings.
About Belite Bio, Inc
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.73 | -0.54 | +29.87% | $0 | ✅ Beat | -7.08% | -5.81% | -2.88% |
| 2026-05-20 | Q1 2026 | -0.63 | -0.45 | +28.57% | $0 | ✅ Beat | +2.62% | +1.71% | +4.60% |
| 2026-03-02 | Q4 2025 | -0.55 | -0.70 | -27.27% | $0 | ❌ Miss | -6.68% | -8.93% | -21.61% |
| 2025-11-10 | Q3 2025 | -0.51 | -0.65 | -27.45% | $0 | ❌ Miss | +3.67% | +3.12% | +31.75% |
| 2025-08-11 | Q2 2025 | -0.44 | -0.50 | -13.64% | $0 | ❌ Miss | -0.54% | -4.65% | -6.01% |
| 2025-05-13 | Q1 2025 | -0.37 | -0.45 | — | $0 | ❌ Miss | +1.17% | +6.44% | +2.05% |
| 2025-03-17 | Q4 2024 | -0.31 | -0.32 | -3.23% | $0 | ❌ Miss | +0.54% | -0.24% | -13.10% |
| 2024-11-12 | Q3 2024 | -0.29 | -0.28 | +3.45% | $0 | ✅ Beat | +3.19% | +5.24% | -18.43% |
Showing last 8 quarters.